Investor Presentaiton

Investor presentation ADA 2019 Slide 23 Progress on several projects since ADA last year June 2018 A A June 2019 Bridging strategy for semaglutide CV labels PIONEER 5, 8 and 10 results PIONEER 2, 3, 4 and 7 results Ziylo acquisition for accelerating PIONEER 9 and 6 glucose responsive insulin results DUAL VIII completed for XultophyⓇ STEP obesity phase 3 OG2023 phase 1 initiated initiated Martin Lange SVP Global Development SELECT obesity CVOT phase 3 initiated REFLECT RWE trial completed for TresibaⓇ US filing of oral semaglutide and CV label for Ozempic® and oral semaglutide AM833 phase 2 initiated LAI287 phase 2 initiated EU and CA filings of oral semaglutide GLP-1 Insulin Obesity & NASH Real-World Evidence Regulatory Partnership with Gilead Science announced novo nordisk

View entire presentation